Bioregulators Khavinson bioregulator tetrapeptideNot FDA-approved · research compound

Cardiogen

Cardiogen (Khavinson)

Evidence: Studied in humans. Example dose: finalize with a provider. Not a fact-check stamp.

100 mcg daily SubQ 10-20 day course

10-20 mg Oral Daily

Cardiac tissue regulatorGene expression modulator

Cardiogen (Ala-Glu-Asp-Arg) is a Khavinson bioregulator tetrapeptide targeting cardiac tissue gene expression. It supports cardiomyocyte function, cardiac extracellular matrix maintenance, and cardiovascular protective pathways. Developed for age-related cardiac decline and cardiac tissue support.

Quick Start

Route

SubQ injection

Start low

100 mcg SubQ

Frequency

10-20 day course

Timing

No fasting required

Starting dose. 100 mcg — Daily

SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

100 mcg daily · SubQ injection · 10-20 day course

conservative starter

100 mcg daily

10-20 day course

Standard

Cardiovascular Bioregulation (Oral capsule)

10-20 mg · Oral · Daily

anecdotal · community

Synthetic tetrapeptide bioregulator for the heart. Usually taken as 1-2 capsules daily for 10-20 days, repeated every 4-6 months. This is the ORAL capsule dose and is not an injection dose. Oral peptide absorption is poor, so this figure is far higher than the injectable protocol on purpose. Do not inject this amount.

10-20 mg

Daily

Reconstitution CalculatorU-100

Vial strength

BAC water

Vials in this mix

Syringe size

Target dose

050100u

Draw to

— units

◆

I will split this dose across more than one syringe

◆

How it works

Cardiogen penetrates cardiomyocytes and interacts with DNA to modulate expression of genes involved in cardiac contractility, extracellular matrix maintenance, antioxidant defense, and cellular stress resistance in heart tissue. Works through epigenetic mechanisms at very low concentrations.

What to expect

Early

Days 1–7

Days 1-10: Gene expression changes initiated.

Mid

Weeks 2–4

Weeks 2-8: Cardiac gene programs established.

Later

Weeks 4–12

Months: Sustained cardiac tissue support.

Evidence

HumanPresent

AnimalPresent

In-vitroPresent

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 100 mcg SubQ daily for a 10-20 day course. No checked abstract administered page-defined Cardiogen (Ala-Glu-Asp-Arg) subcutaneously at this dose and course length.

Mechanism: cardiomyocyte penetration and direct DNA-mediated regulation of cardiac genes. Exact-name results involved rat tissue explants, prostate fibroblasts, or a rat sarcoma model; none stated the page’s sequence-specific cardiomyocyte/DNA mechanism.

Primary safety concern / excellent tolerability at the displayed regimen. No checked human SubQ safety abstract for the page-defined molecule and regimen was found.

The honest take

◆

Cardiac tissue support

Russian clinical data supports improved cardiac markers in elderly. Bioregulatory mechanism targets cardiac-specific gene expression.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

◆

Pin alone. Cardiogen must not share a syringe with anything else, whatever the pharmacology says. PIN ALONE. Khavinson bioregulator.

Documented together

SS-31Cardiogen targets cardiac gene expression, SS-31 targets cardiac mitochondria. Complementary cardiac support. Pin separately.

VesiluteCardiogen cardiac + Vesilute vascular. Complementary cardiovascular support. Run in sequence.

Keep separate

GHK-CuCopper degrades bioregulator peptides.

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Side effects & safety

Commonly reported

Very well tolerated
Mild injection site irritation

Less common & notes

Monitor cardiovascular parameters if on cardiac medications.
Excellent safety profile.

Pharmacokinetics

Illustrative plasma concentration · 2.1 h

Half-life

0.5h

Peak · Tmax

0.08h

Elimination

2.5h

Bioavailability

~100%

SubQ

Duration of action

Weeks to months (cardiac gene expression changes persist long after peptide clearance)

Clearance

Rapid enzymatic degradation (peptidases); renal excretion of amino acid components

Storage. Standard BAC water 2-8C. 21-28 days.

Regulatory status

Not FDA-approved. Research peptide. Used in Russian clinical practice.

Put it to work

Calculate, log & track

Open Cardiogen straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Cardiogen in the app →

Go deeper

The guide & community

The complete Cardiogen walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community